-- Days : -- HRS : -- MIN : -- SEC

Register Now →

Subscribe

News
Video
Podcasts
Journals
Conferences
Events
Resources
CE
About AJMC
Subscribe

Spotlight -

Free In-Person Regional Events Focused on Oncology and Population Health

Muta M. Issa, MD, MBA

Articles by Muta M. Issa, MD, MBA

Comparative Analysis of Alpha-blocker Utilization in Combination With 5-Alpha Reductase Inhibitors for Enlarged Prostate in a Managed Care Setting Among Medicare-aged Men

ByMuta M. Issa, MD, MBA,Pei-Jung Lin, PhD,Michael T. Eaddy, PharmD, PhD,Manan B. Shah, PharmD, PhD,E. Anne Davis, PharmD, MS

May 1st 2008

A Large Retrospective Analysis of Acute Urinary Retention and Prostate-related Surgery in BPH Patients Treated with 5-alpha Reductase Inhibitors: Dutasteride Versus Finasteride

ByMuta M. Issa, MD, MBA,M. Chris Runken, PharmD,Amy L. Grogg, PharmD,Manan B. Shah, PharmD, PhD

February 1st 2007

Medical Therapy for Benign Prostatic Hyperplasia - Present and Future Impact

ByMuta M. Issa, MD, MBA,Timothy S. Regan, BPharm, RPh, CPh

February 1st 2007

Clinical and Economic Outcomes in Patients Treated for Enlarged Prostate

ByMichael James Naslund, MD, MBA,Muta M. Issa, MD, MBA,Amy L. Grogg, PharmD,Michael T. Eaddy, PharmD, PhD,Libby Black, PharmD

March 1st 2006

An Assessment of the Diagnosed Prevalence of Diseases in Men 50 Years of Age or Older

ByMuta M. Issa, MD, MBA,Thomas C. Fenter, MD,Libby Black, PharmD,Amy L. Grogg, PharmD,Eric J. Kruep, PharmD, MS

March 1st 2006

Latest Updated Articles

Trending on AJMC

ATTR-CM Incidence, Prevalence Rose Sharply in the US

CDC Officially Ends Hantavirus Response as Outbreak Risk Recedes

First Generic of Priftin Approved by FDA for Tuberculosis Treatment and Prevention

Mixed Phase 3 Results for IB6-Targeting ADC Raise Questions on Optimal Use in NSCLC

Natera's Moshkevich Discusses TOMR Approach and the Future of MRD-Guided Care